Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00108511
Status:
COMPLETED
Last Update Posted:
2009-01-21
First Post:
2005-04-15
Brief Title:
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol GPI Phospholipase D and Triglycerides
Sponsor:
US Department of Veterans Affairs
Organization:
VA Office of Research and Development
Study Overview
Official Title:
Effect of Gemfibrozil on Serum GPI Phospholipase D and Triglycerides
Status:
COMPLETED
Status Verified Date:
2007-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to examine the role of glycosylphosphatidylinositol-specific phospholipase D GPI-PLD in triglyceride metabolism
Detailed Description:
Increased fasting serum triglyceride levels are associated with an increased risk of coronary artery disease However triglyceride levels in the postprandial state are a more sensitive marker of coronary artery disease Postprandial elevations in triglycerides result from a decrease in the catabolism of triglyceride-rich lipoproteins ie chylomicrons and very low density lipoproteins VLDL This leads to an accumulation of atherogenic remnants of triglyceride-rich lipoproteins Although fasting triglycerides are the best predictors of postprandial triglycerides differences in fasting triglycerides only partially account for the variation in magnitude of postprandial triglycerides Recently we have identified a new protein involved in triglyceride-rich lipoprotein catabolism glycosylphosphatidylinositol-specific phospholipase D GPI-PLD We have shown that elevated levels of GPI-PLD are associated with increased fasting triglyceride levels Serum GPI-PLD is associated with high density lipoproteins HDL in the fasting state and exchange onto VLDL in the postprandial state Hepatic GPI-PLD decreases triglyceride-rich lipoprotein catabolism in the liver Hepatic and serum GPI-PLD levels are decreased by peroxisome proliferator receptor PPAR alpha agonist treatment which also reduces fasting and postprandial triglycerides The central hypothesis of this application is that variations in GPI-PLD expression account for a portion of the differences in fasting and postprandial triglycerides among humans
The objective of this proposal is to determine the role of GPI-PLD in regulating fasting triglycerides and post-prandial hypertriglyceridemia in humans This will be accomplished by conducting a double blind placebo controlled study in humans examining the effect of gemfibrozil on fasting and postprandial triglycerides in relationship to the variation and changes in GPI-PLD before and after gemfibrozil
Our specific objectives are
1a Determine the extent to which variations in GPI-PLD account for differences in fasting and postprandial triglycerides
1b Establish the degree to which the lowering of fasting and postprandial triglycerides by gemfibrozil is accounted for by changes in GPI-PLD
2 Quantify the changes in serum GPI-PLD and distribution of GPI-PLD among lipoproteins in the postprandial state
This will be the first prospective bench-to-bedside study examining the role of GPI-PLD in triglyceride metabolism This proposal will be the first in humans examining 1 the role of a novel protein GPI-PLD in triglyceride metabolism and 2 the effect of gemfibrozil a drug currently used clinically to lower triglyceride levels on GPI-PLD levels in humans It is expected that the results from this study will increase our understanding of triglyceride metabolism and develop new information in understanding the regulation of GPI-PLD and its relationship to triglyceride metabolism
The objective of this proposal is to determine the role of GPI-PLD in regulating fasting triglycerides and post-prandial hypertriglyceridemia in humans This will be accomplished by conducting a double blind placebo controlled study in humans examining the effect of gemfibrozil on fasting and postprandial triglycerides in relationship to the variation and changes in GPI-PLD before and after gemfibrozil
Our specific objectives are
1a Determine the extent to which variations in GPI-PLD account for differences in fasting and postprandial triglycerides
1b Establish the degree to which the lowering of fasting and postprandial triglycerides by gemfibrozil is accounted for by changes in GPI-PLD
2 Quantify the changes in serum GPI-PLD and distribution of GPI-PLD among lipoproteins in the postprandial state
This will be the first prospective bench-to-bedside study examining the role of GPI-PLD in triglyceride metabolism This proposal will be the first in humans examining 1 the role of a novel protein GPI-PLD in triglyceride metabolism and 2 the effect of gemfibrozil a drug currently used clinically to lower triglyceride levels on GPI-PLD levels in humans It is expected that the results from this study will increase our understanding of triglyceride metabolism and develop new information in understanding the regulation of GPI-PLD and its relationship to triglyceride metabolism
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None